Abstract

FORMULATION AND EVALUATION OF DASATINIB IMMEDIATE RELEASE TABLETS

B.Rasmitha Reddy*, B.Venkateswara Reddy, K.Navaneetha

ABSTRACT

Dasatinib is a selective Tyrosine Kinase Inhibitor (TKI) used in treatment of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). Dasatinib have become first line drug in the pharmacotherapy of patients with CML. This is because the drug possesses tolerability and safety advantages over the other Tyrosine Kinase Inhibitors. Tablets of Dasatinib were prepared using different superdisintegrants (Sodium Starch Glycolate, Crosscarmellose, and Crospovidone) by wet granulation method.Nine formulations (F1-F9) of immediate release oral tablets were prepared by using different disintegrants to get desired release profile.The drug-excipients interaction was investigated by FTIR. The granules and tablets of Dasatinib evaluated for various pre and post compression parameters like Angle of repose Compressibility index, Hausner’s ratio, Tablet hardness, Friability, Weight variation, Drug content and in vitro dissolution. Their results were found satisfactory. DSC studies have shown that drug is stable in the formulation. It is concluded that in vitro dissolution studies show the release is in the following order of superdisintegrants: Crosscarmellose > Sodium Starch Glycolate > Crospovidone. Maximum in vitro dissolution was found to be with Formulation F-2 and it clearly shows due to Crosscarmellose (7.9%).

Keywords: Dasatinib, Crosspovidone,Crosscarmellose sodium,Sodium starch glycolate.